1. Home
  2. Search

Search

Search results

59 results found

Nucera Lab

Nucera Lab at BIDMC, focus on preclinical models of human thyroid cancer with an emphasis on mechanisms of metastatic networks, new models of in vitro angiogenesis, tumor microenvironment, and metabolic regulations, using and dissecting new targeted therapies anti-BRAFV600E.

The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.

Publication: Journal Article
Iesato, Asumi, Stephanie Li, Peter M Sadow, Mohammadreza Abbasian, Ara Nazarian, Jack Lawler, and Carmelo Nucera. 2023. “The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.”. Thyroid : Official Journal of the American Thyroid Association 33 (7): 835-48.

Carmelo Nucera, MD, PhD

Person: Associate Professor of Pathology, Harvard Medical School, Board Director in the International Thyroid Oncology Group (ITOG), Member of the Steering Committee at the Center for Vascular Biology and Biomedical Research (CVBR), BIDMC/HMS, Boston
Dr. Nucera is an Associate Professor at Harvard Medical School in the field of Thyroid Cancer, and he was recently awarded from the American Thyroid Association and from the NIH/NCI for Thyroid Cancer Research and BRAF V600E. Dr. Nucera is developing his own independent research program in the CVBR...